R
About RITUXAN

Important Safety Information

RITUXAN for Non-Hodgkin’s Lymphoma Overview

RITUXAN® is a monoclonal antibody that has been used by thousands of patients worldwide. And it has been used for over a decade to treat certain types of NHL. RITUXAN specifically targets a marker (called CD20) on the B-cells in which most non-Hodgkin’s lymphoma (NHL) starts.

The history of RITUXAN in non-Hodgkin’s lymphoma

Ongoing therapy after CVP

Ongoing therapy after CVP

Healthy B-cells help your body fight infection. But in NHL, some B-cells become cancerous and form tumors. RITUXAN targets a marker on the B-cells in tumors. It also targets healthy B-cells. But it leaves most other types of cells alone.

However, RITUXAN does have side effects. RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection). Be sure to read the Medication Guide and full Prescribing Information before each RITUXAN treatment.

Treating different types of non-Hodgkin’s Lymphoma

RITUXAN is an effective part of treatment for many patients with certain types of NHL. RITUXAN may be used to treat 2 main types of NHL.

*
CVP chemotherapy: A type of chemotherapy that consists of the drugs cyclophosphamide, vincristine, and prednisone or prednisolone.
†
CHOP chemotherapy: A type of chemotherapy that consists of the drugs cyclophosphamide, doxorubicin, vincristine, and prednisone.
“Doing research isn’t so much about knowing a lot of facts. It’s about formulating questions. So have a list of questions ready for your doctor.” —Mike, RITUXAN patient

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

 

Indications and Important Safety Information

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

People with serious infections should not receive RITUXAN.

Important Safety Information:

  • RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor

Please see full Prescribing Information, including Medication Guide.